Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 24, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 2,150,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,245.79 pence per share.
- Treasury Holdings: Following the purchase, GSK holds 462,114,158 shares in Treasury.
- Treasury Percentage: Treasury shares represent 8.31% of total voting rights.
- Shares in Issue: 5,562,694,675 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through the repurchase of 2,150,000 shares on October 24, 2007. This transaction increased the company's Treasury share count to 462,114,158. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on future operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total cost of the repurchase by multiplying 2,150,000 shares by 1,245.79 pence.
- Confirm the updated total voting rights denominator (5,562,694,675 shares) for compliance with disclosure rules.
- Note that the Treasury shareholding now stands at 8.31% of total voting rights.
- Recognize that this filing is a regulatory disclosure of a capital transaction and does not contain operational or financial performance results.